Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Net: 2018-2025

  • China SXT Pharmaceuticals' Receivables - Net fell 19.70% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 19.70%. This contributed to the annual value of $3.4 million for FY2025, which is 11.08% up from last year.
  • China SXT Pharmaceuticals' Receivables - Net amounted to $1.3 million in Q3 2025, which was down 60.51% from $3.4 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Receivables - Net high stood at $4.8 million for Q1 2021, and its period low was $1.3 million during Q3 2023.
  • In the last 3 years, China SXT Pharmaceuticals' Receivables - Net had a median value of $2.3 million in 2023 and averaged $2.3 million.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Receivables - Net slumped by 30.41% in 2021 and then increased by 26.93% in 2024.
  • China SXT Pharmaceuticals' Receivables - Net (Quarterly) stood at $3.9 million in 2021, then fell by 14.27% to $4.1 million in 2022, then plummeted by 30.00% to $1.3 million in 2023, then increased by 26.93% to $1.7 million in 2024, then decreased by 19.70% to $1.3 million in 2025.
  • Its Receivables - Net was $1.3 million in Q3 2025, compared to $3.4 million in Q1 2025 and $1.7 million in Q3 2024.